Rajavelu Esther
- SEC CIK
- 0001903716
In the past year, 4 open-market sale filings worth $406.8K and no purchases.
Current role at each company
- SPRO Spero Therapeutics, Inc.See Remarksas of May 6, 2026
- FULC Fulcrum Therapeutics, Inc.Chief Financial Officeras of Feb 13, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $406.8K
- 4 filings
- Net
- −$406.8K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Rajavelu Esther as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
SPRO Spero Therapeutics, Inc.
See Remarks6 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2024 (view filing) | Nov 7-8 | 5 days | Rajavelu EstherCFO & CBO | SSale | −40.6K | $1.31 | −$53.0K | −9.7%379.3K after | 2 lots |
| Feb 5, 2025 (view filing) | Feb 5 | Same day | Rajavelu EstherCFO & CBO | SSale | −20.7K | $0.78 | −$16.1K | −2.8%724.7K after | |
| Nov 12, 2025 (view filing) | Nov 7 | 5 days | Rajavelu EstherSee Remarks | SSale | −40.3K | $2.37 | −$95.4K | −4.4%869.5K after | |
| Feb 4, 2026 (view filing) | Feb 2 | 2 days | Rajavelu EstherSee Remarks | SSale | −18.4K | $2.20 | −$40.6K | −1.6%1.10M after | |
| Feb 9, 2026 (view filing) | Feb 6 | 3 days | Rajavelu EstherSee Remarks | SSale | −87.9K | $2.36 | −$207.5K | −8.0%1.01M after | 2 lots |
| May 6, 2026 (view filing) | May 4 | 2 days | Rajavelu EstherSee Remarks | SSale | −25.2K | $2.51 | −$63.4K | −2.5%986.9K after |